ViiV trials long-acting, two-drug HIV regimen

ViiV trials long-acting, two-drug HIV regimen

ViiV Healthcare has kicked off a late-stage study testing a long-acting, two-drug regimen of its cabotegravir and Janssen’s rilpivirine in virally suppressed adults with HIV-1 infection.

The Phase III ATLAS-2M study is designed to show non-inferior antiviral activity, at 48 weeks of treatment, of long-acting forms of cabotegravir and rilpivirine, administered every eight weeks, compared four-week administration.

It will also evaluate patient satisfaction and provide comparative data on antiviral activity, pharmacokinetics, safety and tolerability out to 96 weeks, the firm noted.

Картинки по запросу cabotegravir                Картинки по запросу rilpivirine

                 cabotegravir                                                        rilpivirine

“We have a patient-centred approach to innovation that seeks to transform how HIV is treated. Our focus on two-drug regimens is key to this strategy,” said John C Pottage, chief scientific and medical Officer at ViiV.

“HIV treatment regimens that do not require daily dosing could be an important part of making HIV feel like a smaller part of patients’ lives and with the ATLAS-2M study, we are evaluating the possibility of maintaining viral suppression with six treatments per year of long-acting cabotegravir and long-acting rilpivirine.”

A first-look at data from the trial is expected sometime in 2019.

The study follows the Phase III ATLAS (involving virally suppressed patients) and FLAIR (involving treatment-naïve patients) studies, assessing monthly dosing with long-acting cabotegravir and long-acting rilpivirine for the treatment of HIV-1 infection. Results from these trials are expected next year.

A two-drug regimen containing ViiV’s dolutegravir, an integrase strand transfer inhibitor, and Janssen’s rilpivirine 25mg, a non-nucleoside reverse transcriptase inhibitor, was approved for patients with HIV in the US last week.

28th November 2017

http://www.pharmatimes.com/

November 28, 2017 / Pharma News